ArticleFrontiers in medicine2026
Extracellular vesicles from Li-Qi-Yang-Yin formula attenuate LPS-stimulated inflammatory injury in human colonic epithelial cells
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Li-Qi-Yang-Yin (LQYY) formula, a traditional Chinese medicine (TCMs) compound, holds potential in managing gastrointestinal disorders. Extracellular vesicles (EVs) derived from medicinal plants are emerging as novel carriers of bioactive compounds, yet their role in multi-herb formulations like LQYY remains largely unexplored. This study aimed to isolate LEVs from the LQYY formula and investigate their protective effects against inflammation and oxidative stress in intestinal epithelial cells. Methods: Li-Qi-Yang-Yin formula contains EVs were isolated from the LQYY decoction via ultracentrifugation. Their physicochemical characteristics were characterized using nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). The metabolite profile was analyzed by untargeted metabolomics. Using a lipopolysaccharide (LPS)-stimulated inflammatory model in human NCM460 colon epithelial cells, we assessed nitric oxide (NO) production, inflammatory cytokine levels, and the expression of proteins in the Toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB) pathway. Results: We successfully isolated LEVs with a typical cup-shaped morphology and an average size of 201.1 nm. Metabolomic analysis identified 862 metabolites, with significant enrichment in fatty acids, phenylpropanoids, and flavonoids. These LEVs were efficiently internalized by NCM460 cells. Pretreatment with LEVs, particularly at a high dose (50 μg/mL), significantly attenuated LPS-stimulated cytotoxicity and intracellular NO overproduction. Furthermore, LEVs dose-dependently suppressed the secretion of pro-inflammatory cytokines (IL-6, TNF-α), promoted the anti-inflammatory cytokine IL-10, and inhibited the activation of the TLR4/NF-κB signaling pathway. Conclusion: Our findings demonstrate that LEVs from the LQYY formula are natural nanoparticles enriched with anti-inflammatory and antioxidant metabolites and can alleviate LPS-stimulated inflammatory injury in human colonic epithelial cells
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.